Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS3416530 A
Publication typeGrant
Publication dateDec 17, 1968
Filing dateMar 2, 1966
Priority dateMar 2, 1966
Publication numberUS 3416530 A, US 3416530A, US-A-3416530, US3416530 A, US3416530A
InventorsRichard A Ness
Original AssigneeRichard A. Ness
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Eyeball medication dispensing tablet
US 3416530 A
Abstract  available in
Images(2)
Previous page
Next page
Claims  available in
Description  (OCR text may contain errors)

Dec. 17, 1968 R. A. NESS 3,416,530

EYEBALL MEDICATION DISPENSING TABLET Filed March 2, 1966 2 Sheets-Sheet l INVENTOR.

R/cHARo A. Nsss BY AT TORNE Y5 Dec. 17, 1968 Filed March 2, 1966 FIG. 3

R. A. NESS EYEBALL MEDICATION DISPENS ING TABLET 2 Sheets-Sheet 2 'AT TORNE Y5 United States Patent 3,416,530 EYEBALL MEDICATION DISPENSING TABLET Richard A. Ness, Fergus Falls, Minn. 56537 Filed Mar. 2, 1966, Ser. No. 531,311 7 Claims. (Cl. 128260) This invention relates generally to the treatment of disseases of the eye, and more particularly, to novel means for dispensing medication to the human eyeball.

At the present time, in the treatment of eye diseases, such as glaucoma, medication is applied to the cornea of the eye in liquid or ointment form. In many cases, to be effective, the application of medication to the cornea should be substantially continuous. Such a procedure is highly inconvenient and confining to the patient. At best, the medication is applied at intervals during the day and night. However, the difiiculty with such periodic application is that the eye receives a massive dose at the time of application, and shortly thereafter, substantially all of the medication is washed away by tears, leaving the eye, particularly the cornea thereof, without medication until the next dose is applied.

An important object of this invention is the provision of means whereby medication is applied to the eyeball continuously over an extended period of time.

Another object of this invention is the provision of a medication dispensing device which may be quickly and easily applied to the eyeball, which will dispense medication thereto-at a predetermined rate of speed, and which may be as quickly and easily removed and replaced when the supply of medicament is exhausted.

Still another object of this invention is the provision of a medication dispensing device having means providing a visual indication of the quantity of medicament available to the eyeball.

Yet another object of this invention is the provision of a medication dispensing device which will conform to the curvature of the sclera so as to fit comfortably in the culde-sac of the conjunctiva between the upper eyelid and the eyeball or globe in radially spaced relation to the cornea, and disposed in the path of tear flow to the cornea, whereby to be responsive to flow of tears to dispense medicament thereto.

To the above ends, I provide a medication dispensing tablet-like body of concavo-convex section and of flexible material and having a smooth curved outline, the concave inner surface of said body having a generally spherical radius conforming substantially to the radius of the scleral portion of an eyeball, the body containing a supply of medicament and adapted to dispense the medicament to tears during flow of said tears from the lacrimal gland toward the cornea of the eyeball, when the body is applied to the eyeball as set forth. The above, and still further highly important objects and advantages of this invention will become apparent from the following detailed specification, appended cl-aims and attached drawings.

Referring to the drawings, which illustrate the invention, and in which like reference characters indicate like parts throughout the several views:

FIG. 1 is a view partly in front elevation and partly diagrammatic, of a human eye, illustrating the use of the invention;

FIG. 2 is a view partly in vertical section and partly diagrammatic of an eyeball and the upper and lower eyelids associated therewith, showing the placement of the medication dispensing tablet of this invention;

FIG. 3 is a view in top plan of a preferred form of medication dispensing tablet of this invention;

FIG. 4 is a longitudinal section, taken on the line 44 of FIG. 3;

FIG. 5 is a transverse section taken substantially on the line 5-5 of FIG. 3;

FIG. 6 is a view corresponding ot FIG. 3 but showing a modified form of tablet;

FIG. 7 is a view in perspective of means for packaging the tablet of this invention; and

FIG. 8 is an enlarged transverse section, taken on the line 88 of FIG. 7.

Referring particularly to FIGS. 1 and 2, a human eye is shown, more or less diagrammatically, as comprising an eyeball 1, and upper and lower eyelids 2 and 3 respectively, the eyeball 1 being covered for the greater parts of its area by the sclera 4 and at its anterior portion by the cornea 5. The eyelids 2 and 3 are lined with a epithelial membrane or conjunctiva 6 which covers the exposed portion of the eyeball including the cornea 5, that portion covering the cornea being transparent, that portion of the conjunctiva 6 which lines the upper eyelid 2 and the underlying portion of the sclera 4 defining a cul-de-sac 7. Upper and lower eyelashes are indicated at 8 and 9 respectively. Other details of the structure of the eyeball 1 are not directly concerned with the structure of the instant invention, detailed showing and description thereof being omitted in the interest of brevity. The usual lacrimal gland associated with the eyeball 1 is shown by dot and dash lines in FIG. 1 and indicated by the numeral 10.

The preferred embodiment of the invention illustrated in FIGS. l-S, a hollow tablet-like body 11, of concavoconvex cross section, is shown as comprising inner and outer walls 12 and 13 respectively, the walls 12 and 13 being joined at their marginal edge portions and defining a chamber 14 that is filled with medicament 15. The marginal juncture of the walls 12 and 13 is rounded, as indicated at 16 in FIGS. 4 and 5, so as to avoid sharp edges and, in the preferred embodiment of the invention, the

outline of the body 11 is bean-shaped or reniform as shown in FIGS. 1 and 3. Communication between the chamber 14 and the exterior of the body 11 is had through a plurality of capillary openings 17 in the walls 12 and 13, as well as through the joined edges thereof. The marginal edges of the inner and outer walls 12 and 13 may be joined together by any suitable means, such as heat-sealing, gluing or the like. Preferably, the capillary openings 17 are disposed in the areas of the walls 12 and 13 adjacent the marginal edges thereof as shown particularly in FIG. 3.

In order that the body 11 may comfortably fit in the cul-de-sac 7, the overall dimensions of the body 11 are quite small. Preferably, the overall length of the body 11 is approximately fifteen millimeters, the width thereof intermediate its ends being in the neighborhood of eleven or twelve millimeters. The outer surface 18, which is adapted to be disposed adjacent the sclera, of the inner wall 12 is generally spherical, having a spherical radius of approximately twelve millimeters, corresponding to the radius of the scleral portion of the eyeball. Obviously, the dimensions noted above may be varied in accordance with eyeballs of different sizes. It will be noted, with reference to FIGS. 4 and 5, that the body 11 is of substantially greater thickness at its central portion than at the marginal edge thereof, whereby to define a chamber 14 of a :size to contain sufiicient highly concentrated medication for adequate treatment over at least a days time. Preferably, the maximum thickness of the body 11 is approximately one to one and one-half millimeters. When the body 11, filled with medicament 15, is placed in the cul-de-sac 7, some of the tear liquid flowing from the lacrimal gland 10 to and across the eyeball 1 will enter the chamber 14 through some of the capillary openings 17, and outwardly therefrom through others of the openings 17, carrying with it some of the medicament 15. Responsive to blinking action of the upper eyelid 2, the tear liquid and medicament mixture will flow over the cornea 5 which absorbs the medicament, thus administering a constant supply of medicament to the cornea until the supply within the chamber 14 is exhausted. Normally, the lacrimal gland is disposed just slightly above and posteriorly or rearwardly of the cul-de-sac 7 in a depression of the upper, outer wall of the orbit, not shown. The flow of tears from the lacrimal gland 10 is generally diagonally across the cornea toward the puncta, as is wellknown to those skilled in this art, the general direction of tear flow being indicated by arrows in FIG. 1.

The tablet-like body 11 may be made from any suitable material that is flexible, biologically inert, nonellergenic, insoluble in tear liquid, and chemically compatible with the medicament in the chamber 14. The walls 12 and 13 of the body 11 may be made from polyethylene or any other of well-known synthetic plastic materials having the above-mentioned characteristics. The medicament in the chamber 14 comprises the desired medication for treatment and a soluble or semi-soluble carrier or matrix, the matrix being of any suitable substance such as gum acacia, gum tragacanth, or the like. The matrix serves to hold the medication together during fabrication of the body 11, and operates as a diluent during the medication dispensing operation of the body 11.

Insertion of the body 11 into the cul-de-sac 7 and removal of the body 11 therefrom is a relatively simple and easy operation. The body 11 may be mounted on or grasped by a suitable tool or holder, not shown, but which may include a minute suction cup for engaging the outer Wall of the body 11. The upper eyelid is raised upwardly and outwardly adjacent the outer corner portion of the eye to open the cul-de-sac 7, and the body 11 inserted and released from the holder. The holder may be one of several types commonly used to insert and remove present day corneal contact lenses, artificial eyes and the like.

The present invention contemplates the use of an indicator dye in the medicament 15 to serve as a visual indication as to the supply of medicament within the chamber 14. For this purpose, a small amount of methylene blue or any suitable dye material is used. So that the medicament 15 may be easily seen, the outer wall 13 of the body 11 is preferably transparent, the inner wall 12 being preferably opaque and having a color in substantial contrast to the color of the medicament 15 or indicator dye.

The modified form of the invention illustrated in FIG. 6 comprises a body 19 that is generally elliptical in outline but which in all other respects is identical to the form of body 11 illustrated in FIGS. 1-5. The parts of the body 19 shown in FIG. 6, corresponding to similar parts of the body 11, are indicated by corresponding reference numerals with prime marks added. Thus the outer wall 13 and the marginal edge 16' are provided with capillary openings 17' and it may be assumed that the body 19 is cross-sectionally similar to the body 11, as shown in FIGS. 4 and 5.

A preferred means for packaging the tablets of this invention is shown in FIGS. 7 and 8. A relatively thick sheet-like base member 20 is shown as being formed to provide a plurality of upwardly opening pockets 21, each for reception of a different one of the tablets of bodies 11 or 19, and having upwardly dished bottom walls 22 which substantially fit the overlying inner wall-s of the bodies 11 or 19. A relatively thin cover sheet 23 overlies the base member 20 and is releasably adhered to the top surface thereof intermediate the pockets 21 and adjacent the marginal edge of the base member 20. Preferably, the base member 20 and cover sheet 23 are made from synthetic plastic sheet material, the cover sheet 23 being preferably transparent so that occupancy of any of the pockets 21 by a tablet may be readily seen. Further, when packaging the tablets, it is desirable to introduce a small amount of the medicament into the various pockets 21 to maintain the outer surfaces of the tablets or bodies 11 or 19 in a moist condition for ease of application to the eyeball. Preferably, the upper surfaces of the base member 20 in the pockets 21 are corrugated, knurled, or otherwise roughened, as indicated at 21a, to prevent the liquid in the pockets 21 from causing the bodies 11 to adhere to the pockets 21, and to break any suction therebetween, which might occur if the surfaces of the pockets 21 were smooth.

It will be appreciated that the outline of the tablets 11 or 19 may be of any curved configuration, such as circular, if desired. Further, the capillary openings 17 and 17 need not be necessarily circular as shown. If desired, the walls 12, 13, 12' and 13 may be made from porous material having the characteristics above described in connection with the body 11. Still further, this invention contemplates a body of the shape or shapes above described, which in itself is a solid body, as distinguished from the bodies 11 or 19 which define inner chambers, but which is in itself sufficiently porous to receive the desired amount of medicament and retain the same until the medicament is gradually leached therefrom under the action of tear flow. In such a modification, the body, not shown, may be made from suitable material of a given color, the medication being dyed to a contrasting color, whereby to provide an indication as to the presence or absence of medication in the porous body.

While I have shown and described a preferred form and a single modification of medication dispensing tablet, it will be understood that the same may be produced in other different shapes, such as circular, and that other modifications may be made without departure from the spirit and scope of the invention, as defined in the claims.

What is claimed is:

1. A medication dispensing tablet for a human eyeball, said tablet comprising a cross-sectionally concavoconvex body of flexible material for insertion into the cul-de-sac of the conjunctiva between the sclera of the eyeball and upper eyelid in generally radially spaced relation to the cornea of the eyeball and in the path of flow of tears from the associated lacrimal gland, said body having a curved outline and an inner concave surface, said concave surface having a generally spherical radius substantially equal to that of the outer scleral surface of an eyeball, and a supply of medicament contained within said body, said body being responsive to flow of tears thereover, when the body is applied to the eyeball, to dispense said medicament to the eyeball generally above the cornea, said body being so constructed and arranged that the rate of dispensing said medicament is dependent upon the rate of flow of tears over said body.

2. The medication dispensing tablet defined in claim 1 in which the marginal outline of said body is generally elliptical.

3. The medication dispensing tablet defined in claim 1 in which the marginal outline of said boy is generally bean-shaped.

4. The medication dispensing tablet defined in claim 1 in which said body comprises a pair of inner and outer walls defining a chamber for the medicament, said body having multiple perforations through at least one of said walls, whereby the medicament in said chamber seeps outwardly fro-m said chamber into the tear flow over said body 5. The medication dispensing tablet defined in claim 1 characterized by dye in said medicament for visual indication of the presence of medicament in said body.

5 6 6. The medication dispensing tablet defined in claim References Cited f! which tthe 03ml Of Of saiddbodayl UNITED STATES PATENTS 1s ransparen, 5211 me icarnen incu ing a me 1cm agent and a soluble matrix, characterized by a dye of a 772,028 10/1904 Carpenter 128-260 given color in said medicament, for visual indication of 5 32? 52223;

the presence of medicament in said chamber.

7. The medication dispensing tablet defined in claim 6 l 4 in which the inner one of the Walls of said body is dyed ADELE EAGER Puma), Exammer' to a given color, the dye in said medicament being of a U S C1 X R color substantially different from that of the colored inner 10 Wall. 128261, 268; 16759; 20663.2

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US772028 *Nov 13, 1903Oct 11, 1904George A CarpenterDevice for putting medicine into eyes.
US2347488 *Apr 5, 1943Apr 25, 1944Danz EmilOptical lens
US3302646 *Jan 10, 1964Feb 7, 1967Charles A BehneyApparatus for treating eye infection
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US3618604 *Jun 9, 1969Nov 9, 1971Alza CorpOcular insert
US3625214 *May 18, 1970Dec 7, 1971Alza CorpDrug-delivery device
US3626940 *May 2, 1969Dec 14, 1971Alza CorpOcular insert
US3630200 *Jun 9, 1969Dec 28, 1971Alza CorpOcular insert
US3814097 *Jan 24, 1973Jun 4, 1974Ici LtdDressing
US3826258 *Feb 7, 1972Jul 30, 1974Abraham SGradual release medicine carrier
US3828777 *Nov 8, 1971Aug 13, 1974Alza CorpMicroporous ocular device
US3845770 *Jun 5, 1972Nov 5, 1974Alza CorpOsmatic dispensing device for releasing beneficial agent
US3853116 *Jul 2, 1973Dec 10, 1974Investors In Ventures IncImplant methods and devices for influencing body fluids
US3926188 *Nov 14, 1974Dec 16, 1975Alza CorpLaminated drug dispenser
US3995635 *Nov 4, 1974Dec 7, 1976Alza CorporationOcular insert
US4136173 *Jan 31, 1977Jan 23, 1979American Home Products Corp.Mixed xanthan gum and locust beam gum therapeutic compositions
US4136177 *Jan 31, 1977Jan 23, 1979American Home Products Corp.Xanthan gum therapeutic compositions
US4136178 *Jan 31, 1977Jan 23, 1979American Home Products Corp.Locust bean gum therapeutic compositions
US4201210 *Nov 28, 1977May 6, 1980The United States Of America As Represented By The Secretary Of AgricultureVeterinary ocular ring device for sustained drug release
US4304226 *Mar 3, 1980Dec 8, 1981The Procter & Gamble CompanyVaginal contraceptive
US4959217 *May 22, 1986Sep 25, 1990Syntex (U.S.A.) Inc.Delayed/sustained release of macromolecules
US5270051 *Oct 15, 1991Dec 14, 1993Harris Donald HEnzyme-orthokeratology
US5378475 *Feb 21, 1991Jan 3, 1995University Of Kentucky Research FoundationSustained release drug delivery devices
US5472436 *Jul 26, 1994Dec 5, 1995Fremstad; Daria A.Ocular appliance for delivering medication
US5626865 *Oct 15, 1992May 6, 1997Advanced Corneal Systems, Inc.Enzyme-orthokeratology
US5773019 *Sep 27, 1995Jun 30, 1998The University Of Kentucky Research FoundationImplantable controlled release device to deliver drugs directly to an internal portion of the body
US5788957 *Sep 12, 1996Aug 4, 1998Advanced Corneal Systems, Inc.Enzyme-orthokeratology
US5876438 *Aug 2, 1993Mar 2, 1999Houston Biotechnology IncorporatedPolymeric device for the delivery of immunotoxins for the prevention of secondary cataract
US5902598 *Aug 28, 1997May 11, 1999Control Delivery Systems, Inc.Sustained release drug delivery devices
US6063116 *Apr 24, 1995May 16, 2000Medarex, Inc.Modulation of cell proliferation and wound healing
US6132735 *Sep 18, 1997Oct 17, 2000Ista Pharmaceutical, Inc.Enzyme-orthokeratology
US6161544 *Jan 28, 1998Dec 19, 2000Keratoform, Inc.Methods for accelerated orthokeratology
US6264971 *Nov 4, 1999Jul 24, 2001Btg International LimitedOcular insert
US6303102Sep 7, 2000Oct 16, 2001Kenneth SchlichteCutaneously applied biodegradable tell-tale having controllable clearing time
US6331313Oct 22, 1999Dec 18, 2001Oculex Pharmaceticals, Inc.Controlled-release biocompatible ocular drug delivery implant devices and methods
US6375972Apr 26, 2000Apr 23, 2002Control Delivery Systems, Inc.Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US6413245Oct 4, 2000Jul 2, 2002Alcon Universal Ltd.Sub-tenon drug delivery
US6413540Sep 12, 2000Jul 2, 2002Alcon Universal Ltd.Drug delivery device
US6416777Sep 19, 2000Jul 9, 2002Alcon Universal Ltd.Ophthalmic drug delivery device
US6669950Jul 1, 2002Dec 30, 2003Alcon, Inc.Ophthalmic drug delivery device
US6699493Nov 28, 2001Mar 2, 2004Oculex Pharmaceuticals, Inc.Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US6756049Dec 17, 2001Jun 29, 2004Bausch & Lomb IncorporatedSustained release drug delivery devices
US6756058Dec 27, 2001Jun 29, 2004Bausch & Lomb IncorporatedSustained release drug delivery devices with multiple agents
US6808719Jul 1, 2002Oct 26, 2004Alcon, Inc.Drug delivery device
US6964781Dec 27, 2001Nov 15, 2005Bausch & Lomb IncorporatedSustained release drug delivery devices with prefabricated permeable plugs
US6986900Nov 5, 2003Jan 17, 2006Alcon, Inc.Ophthalmic drug delivery device
US6991808Jan 23, 2002Jan 31, 2006Bausch & Lomb Inc.Process for the production of sustained release drug delivery devices
US7033605Dec 22, 2003Apr 25, 2006Allergan, Inc.Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US7094226Nov 12, 2003Aug 22, 2006Alcon, Inc.Ophthalmic drug delivery device
US7181287Jul 24, 2002Feb 20, 2007Second Sight Medical Products, Inc.Implantable drug delivery device
US7527621Aug 16, 2006May 5, 2009Second Sight Medical Products, Inc.Implantable drug delivery device
US7563255May 2, 2002Jul 21, 2009Massachusetts Eye And Ear InfirmaryImplantable drug delivery device and use thereof
US7585517Sep 20, 2004Sep 8, 2009Macusight, Inc.Transscleral delivery
US7621907Mar 11, 2003Nov 24, 2009Alcon, Inc.Implantable drug delivery system
US7625582Apr 20, 2007Dec 1, 2009Allergan, Inc.Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US7708711Nov 12, 2003May 4, 2010Glaukos CorporationOcular implant with therapeutic agents and methods thereof
US7767223Jul 11, 2005Aug 3, 2010Allergan, Inc.Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use
US7824704Aug 15, 2005Nov 2, 2010Surmodics, Inc.Controlled release bioactive agent delivery device
US7846468Nov 3, 2008Dec 7, 2010Allergan, Inc.Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US7943162Dec 7, 2006May 17, 2011Alcon, Inc.Drug delivery device
US7976862Aug 15, 2005Jul 12, 2011Surmodics, Inc.Controlled release bioactive agent delivery device
US8021680Apr 29, 2004Sep 20, 2011Surmodics, Inc.Controlled release bioactive agent delivery device
US8034366Oct 11, 2011Allergan, Inc.Ocular implant made by a double extrusion process
US8034369Sep 12, 2005Oct 11, 2011Surmodics, Inc.Controlled release bioactive agent delivery device
US8034370Oct 31, 2007Oct 11, 2011Allergan, Inc.Ocular implant made by a double extrusion process
US8043628Oct 31, 2007Oct 25, 2011Allergan, Inc.Methods for reducing edema
US8071120Mar 30, 2006Dec 6, 2011Allergan, Inc.Methods for treating neovascularization and intravitreal implants
US8088407Sep 7, 2007Jan 3, 2012Allergan, Inc.Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US8096972Dec 19, 2003Jan 17, 2012Johns Hopkins UniversityDevices for intraocular drug delivery
US8167855Aug 25, 2004May 1, 2012Vista Scientific LlcOcular drug delivery device
US8177747Nov 30, 2010May 15, 2012Alcon Research, Ltd.Method and apparatus for drug delivery
US8222271Mar 23, 2007Jul 17, 2012Santen Pharmaceutical Co., Ltd.Formulations and methods for vascular permeability-related diseases or conditions
US8242099Oct 12, 2011Aug 14, 2012Allergan, Inc.Implants and methods for treating inflammation-mediated conditions of the eye
US8246974Apr 8, 2005Aug 21, 2012Surmodics, Inc.Medical devices and methods for producing the same
US8277830Oct 4, 2011Oct 2, 2012Forsight Vision4, Inc.Posterior segment drug delivery
US8287504Jul 22, 2010Oct 16, 2012Vista Scientific LlcOcular drug delivery device
US8298578Oct 4, 2011Oct 30, 2012Forsight Vision4, Inc.Posterior segment drug delivery
US8313763Feb 15, 2007Nov 20, 2012Tolmar Therapeutics, Inc.Sustained delivery formulations of rapamycin compounds
US8318070Nov 27, 2012Allergan, Inc.Ocular implant made by a double extrusion process
US8348877May 3, 2010Jan 8, 2013Dose Medical CorporationOcular implant with therapeutic agents and methods thereof
US8367097May 12, 2010Feb 5, 2013Santen Pharmaceutical Co., Ltd.Liquid formulations for treatment of diseases or conditions
US8372036May 5, 2010Feb 12, 2013Alcon Research, Ltd.Multi-layer heat assembly for a drug delivery device
US8382725 *Jun 20, 2009Feb 26, 2013Michael CampionEye coloring systems
US8399006Jan 29, 2010Mar 19, 2013Forsight Vision4, Inc.Posterior segment drug delivery
US8469934Jan 25, 2011Jun 25, 2013Alcon Research, Ltd.Pulsatile peri-corneal drug delivery device
US8486052Dec 27, 2010Jul 16, 2013The Johns Hopkins University School Of MedicineReservoir device for intraocular drug delivery
US8486960Jun 21, 2012Jul 16, 2013Santen Pharmaceutical Co., Ltd.Formulations and methods for vascular permeability-related diseases or conditions
US8492400Feb 9, 2007Jul 23, 2013Santen Pharmaceutical Co., Ltd.Stable formulations, and methods of their preparation and use
US8506987Aug 19, 2011Aug 13, 2013Allergan, Inc.Ocular implant made by a double extrusion process
US8623395Aug 5, 2011Jan 7, 2014Forsight Vision4, Inc.Implantable therapeutic device
US8632511May 5, 2010Jan 21, 2014Alcon Research, Ltd.Multiple thermal sensors in a multiple processor environment for temperature control in a drug delivery device
US8637070Feb 9, 2006Jan 28, 2014Santen Pharmaceutical Co., Ltd.Rapamycin formulations and methods of their use
US8658667Jun 24, 2013Feb 25, 2014Santen Pharmaceutical Co., Ltd.Stable formulations, and methods of their preparation and use
US8663639Aug 18, 2008Mar 4, 2014Santen Pharmaceutical Co., Ltd.Formulations for treating ocular diseases and conditions
US8679078Sep 17, 2012Mar 25, 2014Vista Scientific LlcOcular drug delivery device
US8715712Nov 28, 2012May 6, 2014Forsight Vision5, Inc.Ocular insert apparatus and methods
US8765166Jul 22, 2013Jul 1, 2014Novaer Holdings, Inc.Drug delivery devices for delivery of ocular therapeutic agents
US8778381Mar 12, 2013Jul 15, 2014Allergan, Inc.Ocular implant made by a double extrusion process
US8795712May 7, 2013Aug 5, 2014Forsight Vision4, Inc.Posterior segment drug delivery
US8802128Jul 21, 2006Aug 12, 2014Allergan, Inc.Steroid-containing sustained release intraocular implants and related methods
US8802129Jul 19, 2013Aug 12, 2014Allergan, Inc.Methods for treating retinopathy with extended therapeutic effect
US8808727Mar 15, 2013Aug 19, 2014Forsight Vision4, Inc.Posterior segment drug delivery
US8828446Apr 26, 2013Sep 9, 2014Allergan, Inc.Method for reducing transplant rejection in the eye and intraocular implants for use therefor
US8905963May 7, 2013Dec 9, 2014Forsight Vision4, Inc.Injector apparatus and method for drug delivery
US8911768Jun 17, 2014Dec 16, 2014Allergan, Inc.Methods for treating retinopathy with extended therapeutic effect
US8927005Jan 14, 2013Jan 6, 2015Santen Pharmaceutical Co., Ltd.Liquid formulations for treatment of diseases or conditions
US8939948Sep 14, 2012Jan 27, 2015Forsight Vision5, Inc.Ocular insert apparatus and methods
US9012437May 3, 2013Apr 21, 2015Allergan, Inc.Implants and methods for treating inflammation-mediated conditions of the eye
US9033911Aug 5, 2011May 19, 2015Forsight Vision4, Inc.Injector apparatus and method for drug delivery
US9066779Jan 3, 2014Jun 30, 2015Forsight Vision4, Inc.Implantable therapeutic device
US9066782Dec 17, 2012Jun 30, 2015Dose Medical CorporationOcular implant with therapeutic agents and methods thereof
US20040092911 *Nov 5, 2003May 13, 2004Yoseph YaacobiOphthalmic drug delivery device
US20040131654 *Oct 30, 2003Jul 8, 2004Yoseph YaacobiOphthalmic drug delivery device
US20040131655 *Oct 30, 2003Jul 8, 2004Yoseph YaacobiOphthalmic drug delivery device
US20040133155 *Dec 19, 2003Jul 8, 2004Varner Sign EricksonDevices for intraocular drug delivery
US20040137034 *Dec 22, 2003Jul 15, 2004Wong Vernon G.Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US20040208909 *May 12, 2004Oct 21, 2004Brubaker Michael JSustained release drug delivery devices
US20050013845 *Nov 12, 2003Jan 20, 2005Warren Stephen L.Adhesive bioerodible ocular drug delivery system
US20050019371 *Apr 29, 2004Jan 27, 2005Anderson Aron B.Controlled release bioactive agent delivery device
US20050112175 *Oct 4, 2004May 26, 2005Yoseph YaacobiDrug delivery device
US20100004609 *Jan 7, 2010Michael CampionEye coloring systems
US20120078362 *May 18, 2010Mar 29, 2012Dose Medical CorporationDrug eluting ocular implant
USB520277 *Nov 4, 1974Feb 17, 1976 Title not available
DE2243986A1 *Sep 7, 1972Mar 29, 1973Alza CorpBiologisch abbaubarer augeneinsatz zur verabreichung eines arzneimittels
DE2547378A1 *Oct 23, 1975Apr 29, 1976Searle & CoVorrichtung mit abgeschlossenen mikrokammern zur abgabe eines arzneimittels
EP1982701A2Apr 19, 2001Oct 22, 2008pSivida IncSustained Release Drug Delivery Devices, Methods of Use, and Methods of Manufacturing Thereof
EP2329821A1Nov 29, 2006Jun 8, 2011GlaxoSmithKline LLCTreatment of ocular neovascular disorders such as macular degeneration, angiod streaks, uveitis and macular edema
EP2374451A2Jul 27, 2006Oct 12, 2011University of Florida Research Foundation, Inc.Histone deacetylase inhibitors (HDAC) that correct protein misfolding and uses thereof
WO1993007840A1 *Oct 15, 1992Apr 29, 1993Advanced Corneal Systems IncEnzyme-orthokeratology
WO1993019707A1 *Apr 2, 1992Oct 14, 1993Bausch & LombOphthalmic article
WO2001030323A2 *Oct 19, 2000May 3, 2001Oculex Pharm IncControlled-release biocompatible ocular drug delivery implant devices and methods
WO2001032140A1Nov 3, 2000May 10, 2001Btg Int LtdOcular insert
WO2010147653A1Jun 16, 2010Dec 23, 2010Bikam Pharmaceuticals, Inc.Opsin-binding ligands, compositions and methods of use
WO2011039648A1Sep 29, 2010Apr 7, 2011Glaxo Wellcome Manufacturing Pte Ltd.Methods of administration and treatment
Classifications
U.S. Classification424/427, 424/9.1, 206/558, 206/438, 206/564, 351/159.2
International ClassificationA61K9/00, A61F9/00
Cooperative ClassificationA61K9/0051, A61F9/0017
European ClassificationA61K9/00M16B, A61F9/00B2